申请人:Intrexon Corporation
公开号:US20160083403A1
公开(公告)日:2016-03-24
The present disclosure provides boron-containing diacylhydrazines having Formula I:
and the pharmaceutically acceptable salts and solvates thereof, wherein A, R
4
, and R
5
are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
本公开提供具有化学式I的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物,其中A、R4和R5的定义如规范中所述。本公开还提供了使用含硼二酰肼类化合物的蜕皮激素受体诱导基因表达系统。因此,本公开对于基因治疗、疾病治疗、大规模蛋白质和抗体的生产、基于细胞的筛选分析、功能基因组学、蛋白质组学、代谢组学以及调节转基因生物的特征等应用非常有用,其中对基因表达水平的控制是必要的。